Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIM1811-03 + sintilimab
- Development stage
- Unknown
- Lead developer
- Simcere Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SIM1811-03 + sintilimab is an investigational combination therapy being evaluated for the treatment of advanced solid tumors and cutaneous T-cell lymphoma. SIM1811-03 is a first-in-class, humanized IgG1 monoclonal antibody targeting tumor necrosis factor type 2 receptor (TNFR2), designed to modulate the tumor microenvironment and inhibit regulatory T cell-mediated immunosuppression. Sintilimab is a fully human IgG4 monoclonal antibody that targets programmed cell death protein 1 (PD‑1) on T cells, blocking its interaction with PD-L1/PD-L2 to enhance anti-tumor immune responses. The combination aims to synergistically enhance immune-mediated tumor cell killing by simultaneously inhibiting two key immunosuppressive pathways[2][5][8].
- Brand names
- Tyvyt
- Other names
- anti-TNFR2 monoclonal antibody (for SIM1811-03)anti-PD-1 monoclonal antibody (for sintilimab)
02
Targets
TNFR2 (Tumor necrosis factor receptor superfamily member 1B)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on SIM1811-03 + sintilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIM1811-03 + sintilimab.